GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00567424|
Recruitment Status : Withdrawn (No longer viable)
First Posted : December 5, 2007
Last Update Posted : April 4, 2013
|Condition or disease||Intervention/treatment||Phase|
|Epilepsy||Drug: GW273225||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-label Evaluation of Drug Interactions, Safety, Tolerability and Efficacy of GW273225 Add-on Treatment of Partial Seizures, Whether or Not Secondarily Generalized|
|Study Start Date :||July 2006|
|Actual Primary Completion Date :||March 2008|
|Actual Study Completion Date :||March 2008|
- Pharmacokinetic drug interactions with the most common inhibiting and inducing antiepileptic drugs AEDs: valproate(VPA), carbamazepine(CBZ) and phenytoin (PHT).
- Safety/tolerability of GW273225 in adults with refractory epilepsy Efficacy of GW273225 in adults with refractory epilepsy Potential initial starting doses for a subsequent placebo-controlled dose-ranging Phase IIb study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00567424
Show 30 Study Locations
|Study Director:||GSK Clinical Trials, MD||GlaxoSmithKline|